for cUTI (complicated urinary tract infection)
CXA-201 (ceftolozane/tazobactam), which is being developed as a first-line intravenous therapy for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, advanced into Phase 3 trials in July 2011…
LEXINGTON, Mass.-- Cubist Pharmaceuticals, Inc. today announced the appointment of Alison Lawton to its Board of Directors. Ms. Lawton is currently Senior Vice President, General Manager Biosurgery, at Genzyme Corporation (now part of Sanofi). With the addition of Ms. Lawton, the Cubist Board of Directors consists of 10 members, nine of whom are independent.
Q: What are your basic job responsibilities? Hernando: I am a senior medical director working in clinical research at Cubist,…
View our Careers page to see all current opportunities with Cubist.
Cubist, in partnership with the New England Patriots Radio Network, 98.5 The Sports Hub, has selected Sean Muller, a science teacher at Merrimack High School, in Merrimack, New Hampshire, to receive the Cubist Pharmaceuticals Science Education Leadership Award.
